Zacks Research Has Pessimistic View of Medifast Q2 Earnings

Medifast, Inc. (NYSE:MED) – Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for Medifast in a report issued on Monday, November 25th. Zacks Research analyst A. Mohta now forecasts that the specialty retailer will earn $0.29 per share for the quarter, down from their previous forecast of $0.37. The consensus estimate for Medifast’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.38 EPS, Q1 2026 earnings at $0.42 EPS and Q2 2026 earnings at $0.43 EPS.

Medifast (NYSE:MED) last issued its quarterly earnings results on Monday, November 4th. The specialty retailer reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.50. Medifast had a return on equity of 15.98% and a net margin of 1.09%. The business had revenue of $140.16 million for the quarter, compared to analyst estimates of $135.45 million. During the same quarter in the prior year, the firm posted $2.12 earnings per share.

Separately, DA Davidson raised Medifast from an “underperform” rating to a “neutral” rating and upped their price target for the company from $16.50 to $17.00 in a research note on Tuesday, November 5th.

Medifast Trading Down 1.6 %

Shares of MED opened at $18.32 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06. Medifast has a 12-month low of $17.07 and a 12-month high of $76.42. The firm has a market capitalization of $200.42 million, a PE ratio of 27.76 and a beta of 1.13. The stock’s fifty day simple moving average is $18.48 and its 200-day simple moving average is $19.83.

Hedge Funds Weigh In On Medifast

Several hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in shares of Medifast by 20.3% in the second quarter. Renaissance Technologies LLC now owns 958,610 shares of the specialty retailer’s stock worth $20,917,000 after acquiring an additional 161,487 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Medifast by 37.8% in the second quarter. Millennium Management LLC now owns 469,216 shares of the specialty retailer’s stock worth $10,238,000 after acquiring an additional 128,719 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Medifast by 117.5% in the second quarter. AQR Capital Management LLC now owns 389,951 shares of the specialty retailer’s stock worth $8,509,000 after acquiring an additional 210,669 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Medifast by 2,000.1% in the second quarter. Acadian Asset Management LLC now owns 338,228 shares of the specialty retailer’s stock worth $7,376,000 after acquiring an additional 322,123 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Medifast by 415.1% in the second quarter. Federated Hermes Inc. now owns 215,090 shares of the specialty retailer’s stock worth $4,693,000 after acquiring an additional 173,337 shares in the last quarter. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.